Aureka Biotechnologies, a company pioneering in data-driven protein design and immune drug discovery platforms, has recently announced a partnership agreement with Alphamab. This collaboration is expected to jointly accelerate innovation in the field of drug discovery.

Aureka Biotechnologies, with its deep research into single-cell functional screening, synthetic biology, and artificial intelligence, leverages its cutting-edge technology platform to make disruptive progress in discovering first-in-class and best-in-class drugs. By combining its rich experience in drug development with the technological innovations of Aureka Biotechnologies, Alphamab is committed to accelerating the development of transformative new pharmaceuticals.

Under this partnership, Aureka Biotechnologies will receive an upfront payment to fund the research efforts and will be entitled to milestone payments and a share of the sales proceeds as the project moves forward.